Characterization of immunomodulatory B-cells and T-cells to generate extremely targeted immunoassays and vaccines
Keywords:
epitope, rubella virus, peptide vaccine, B and T cell peptideAbstract
Introduction: The Rubella virus has worldwide occurrence and congenital Rubella syndrome are widely recognized as emerging infection in several parts of the world. Methodology: We investigated for peptide vaccine with specific T and B-cell epitopes was identified through bioinformatics-based approaches. These were identified utilizing available Rubella virus E1 glycoprotein sequence databases. The outer-membrane glycoprotein, E1 is a target protein for the prediction of best antigens. Results: The bioinformatics online software Bepipred 2 was used for prediction of potential B-cell epitope (pfcntphgqlevqvppdpgd) was identified and it has shown high conversation against E1 glycoprotein and few other bioinformatics online software NetMHCpan, IEDB and NetCTL was used to identify maximum surface-exposed residues. T-Cell epitope (rpvalpral) was identified and shown to be conserved to E1 Glycoprotein. Predicted epitopes were found to had promiscuous class-I major histocompatibility complex binding affinity to major histocompatibility complex super types, antigenicity scores and high proteasomal cleavage. The three-dimensional modelled structures was created using I-TASSER online server for highlighting the predicted T- and B- cell epitopes. Conclusion: The predicted T and B cell epitope could be used for development of immunoglobulin assay and vaccines.
Downloads
References
Dominguez G, Wang CY, Frey TK Sequence of the genome RNA of rubella virus: evidence for genetic rearrangement during togavirus evolution. Virology (1990) 177: 225-238.
Battisti AJ, Yoder JD, Plevka P, Winkler DC, Prasad VM, et al. Cryo-electron tomography of rubella virus. J Virol (2012)86: 11078-11085.
George S, Viswanathan R, Sapkal GN. Molecular aspects of the teratogenesis of rubella virus. Biol Res. 2019 Aug 28;52(1):47.
WHO organization (2011) Weekly epidemiological record. Rubella vaccines: WHO position paper 86: 301-316.
Best JM (2007) Rubella. Semin Fetal Neonatal Med 12: 182-192.
Atkinson W, Wolfe S, Hamborsky J Epidemiology and Prevention of Vaccine-preventable Diseases, Centers for Disease Control and Prevention. 2011
Muliyil DE, Singh P, Jois SK, Otiv S, Suri V, Varma V, et al Sero-prevalence of rubella among pregnant women in India, 2017. Vaccine. 2018 Dec 18;36(52):7909-7912.
Mitchell LA, Tingle AJ, Décarie D, Shukin R Identification of rubella virus T-cell epitopes recognized in anamnestic response to RA27/3 vaccine: associations with boost in neutralizing antibody titer. Vaccine (1999) 17: 2356-2365
Petrova EK, Dmitrieva AA, Trifonova EA, Nikitin NA, Karpova OV The key role of rubella virus glycoproteins in the formation of immune response, and perspectives on their use in the development of new recombinant vaccines. Vaccine (2016) 34: 1006-1011
Gießauf A, Letschka T, Walder G, Dierich MP, Würzner R A synthetic peptide ELISA for the screening of rubella virus neutralizing antibodies in order to ascertain immunity. J Immunol Methods (2004) 287: 1-11.
Seto NO, Gillam S Expression and characterization of a soluble rubella virus E1 envelope protein. J Med Virol (1994) 44: 192-199.
Yavuz ST, Sahiner UM, Sekerel BE, Tuncer A, Kalayci O, et al. Anaphylactic reactions to measles–mumps–rubella vaccine in three children with allergies to hen’s egg and cow’s milk. Acta Paediatr (2011) 100: e94-e96.
Sukumaran L, McNeil MM, Moro PL, Lewis PW, Winiecki SK, et al. Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003- 2013. Clin Infect Dis (2015) 60: e58-65
Binnicker MJ, Jespersen DJ, Harring JA. Multiplex detection of IgM and IgG class antibodies to Toxoplasma gondii, rubella virus, and cytomegalovirus using a novel multiplex flow immunoassay. Clin Vaccine Immunol. 2010; 17(11):1734-1738
Jespersen MC, Peters B, Nielsen M, Marcatili P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res 2017
Larsen JEP, Lund O, Nielsen M. Improved method for predicting linear B‐cell epitopes. Immunome Res. 2006;2:2.
Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. The I‐TASSER suite: protein structure and function prediction. Nat Methods. 2015;12:7‐8.
Lovell SC, Davis IW, Arendall WB 3rd, de Bakker PI, Word JM, Prisant MG, Richardson JS, Richardson DC. Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins. 2003 Feb 15;50(3):437-50.
Reliable B Cell Epitope Predictions: Impacts of Method Development and Improved Benchmarking Jens Vindahl Kringelum, Claus Lundegaard, Ole Lund, and Morten Nielsen
Plos Computational Biology, 2012
Kringelum JV, Lundegaard C, Lund O, Nielsen M. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput Biol. 2012;8(12):e1002829.
Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics. 2016 Feb 15;32(4):511-7.
Bhasin M, Raghava GP. Classification of nuclear receptors based on amino acid composition and dipeptide composition. J Biol Chem. 2004 May 28;279(22):23262-6.
Nielsen R, Williamson S, Kim Y, Hubisz MJ, Clark AG, Bustamante C. Genomic scans for selective sweeps using SNP data. Genome Res. 2005;15(11):1566 1575.
Shaz, S. K. (2019). Contribution of viruses to cancer and its global burden. Glob J Cancer Ther, 5(1), 012-015.
Anjum, A., Siddique, H., Rabaan, A. A., Alhumaid, S., Garout, M., Almuthree, S. A., ... & Zeshan, B. (2023). Evaluation of Hematological, Biochemical Profiles and Molecular Detection of Envelope Gene (gp-41) in Human Immunodeficiency Virus (HIV) among Newly Diagnosed Patients. Medicina, 59(1), 93.
Shaz, S. K., Ullah, N., & Rafique, I. (2019). Prevalence of Hepatitis B and C in District Dir Upper, Khyber Pakhtunkhwa, Pakistan. Glob J Clin Virol, 4(1), 8-18.
Shaz, S. K., Swati, H. K., & Khan, Y. (2019). Outbreak of hepatitis-B, epidemiology, and transmission in provinces of Pakistan.
Published
How to Cite
Issue
Section
Copyright (c) 2023 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
